HSN Leadership

Cynthia I. Campbell, PhD, MPH

Health System Node Principal Investigator
Kaiser Permanente Division of Research

Dr. Cynthia Campbell is a Senior Research Scientist at the Division of Research, Kaiser Permanente Northern California, where she co-directs the Center for Addiction and Mental Health Research. She is also an Adjunct Professor in the Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, and an Associate Professor at the Bernard J. Tyson School of Medicine.

With two decades of experience, Dr. Campbell’s research on substance use and comorbidity leverages electronic health record data, patient surveys, and pragmatic trials. Her work focuses on access to care, pain and substance use, prescription opioids and cannabis use, and related health policies.

Dr. Campbell led a PCORI-funded trial of a patient activation intervention in primary care for patients using opioids long term, as well as a NIDA-funded trial testing differences in psychosocial service intensity for patients in substance use disorder treatment. She was the lead investigator of the Prescription Opioid Registry study (CTN-0084), which developed a multi-site prescription opioid registry based on electronic health record data across 10 health systems to address important questions on the opioid crisis.

She was the co-lead investigator of the D-TECT study (CTN-0084-A-2; co-lead investigator Dr. Lisa Marsch) that was a digital phenotyping of patients receiving buprenorphine medication for opioid use disorder to establish methodological feasibility and predict relapse. Dr. Campbell also led CTN-0117, that examined pandemic related changes in substance use disorder treatment utilization, and has been a co-investigator on: HEDIS AOD-IET Measure Performance (CTN-0072-OT), the PROUD Trial (CTN-0074), Cannabis use and Pregnancy (CTN-0140), and Insurance Instability and Mortality (CTN-0141). ​

Dr. Campbell is supported by Senior Project Manager or HSN Project Director Monique Buffler. Ms. Buffler is the administrative lead contact for HSN and manages activities at Kaiser Permanente Northern California.

Ingrid A. Binswanger, MD, MPH, MS

Health System Node Principal Investigator
Kaiser Permanente Colorado Institute for Health Research

Dr. Ingrid A. Binswanger is a Senior Clinician Investigator at the Institute for Health Research, Kaiser Permanente Colorado. She is also a Professor of Medicine at the University of Colorado School of Medicine and Adjunct Professor of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine.

Dr. Binswanger’s research focuses on preventing overdose, improving treatment provision and outcomes in health systems, and improving healthcare transitions between carceral and community settings. Her prior work includes practice-changing studies on death after release from prison, pragmatic trials of strategies to enhance naloxone provision in health systems, and multisite studies of the intended and unintended effects of opioid tapering and discontinuation.

After a decade of involvement in the NIDA CTN Health Systems Node as Site PI for Kaiser Permanente Colorado, she joined the Health Systems Node leadership team as Multiple PI in 2025. She is currently a site lead for Insurance Instability and Mortality (CTN-0141) and site PI for Office-based Methadone Trial – EMBOSS (CTN-0131).

She was Co-I on the following completed CTN studies: HEDIS AOD-IET Measure Performance (CTN-0072), Evaluation of Medical Cannabis Documentation (CTN-0077), Prescription Opioid Registry (CTN-0084), and Determining Optional Duration of Buprenorphine Treatment (CTN-0084-A-1). And she was site PI for an exemplar site of the PROUD trial (CTN-0074).

Dr. Binswanger is dual board-certified in internal medicine and addiction medicine. As a physician with the
Colorado Permanente Medical Group, she sees patients in the Rapid Start Clinic, Chemical Dependency Treatment Services at Kaiser Permanente Colorado. 

Gwen Lapham, PhD, MPH, MSW

Health System Node Principal Investigator
Kaiser Permanente Washington Health Research Institute

Dr. Gwen Lapham is an Associate Investigator at the Kaiser Permanente Washington Health Research Institute, an Affiliate Associate Professor in the Department of Health Systems and Population Health at the University of Washington, and an Assistant Professor in the Department of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine. She is an addictions health services researcher with more than 15 years of experience developing, implementing, and evaluating strategies to improve the prevention and treatment of unhealthy substance use in medical settings. Her research focuses on primary care interventions, implementation science, pragmatic clinical trials, and the use of electronic health record (EHR) data and surveys to improve care for patients with substance use disorders. Dr. Lapham has been an investigator in the NIDA CTN Health Systems Node since its inception and became a Multiple Principal Investigator of the Node in 2026.

Within the CTN, Dr. Lapham led the Evaluation of Medical Cannabis Documentation study (CTN-0077-OT), which assessed EHR, survey, and primary care measures of cannabis use and medical cannabis use. She was site lead investigator for the HEDIS AOD-IET Measure Performance study (CTN-0072-OT) and served in multiple leadership roles on the PROUD Trial (CTN-0074), including leading the primary publication reporting the trial’s year 3 outcomes. She has also contributed to studies examining prenatal cannabis use (CTN-0140) and validation of the DSM-5 Substance Use Symptom Checklist (CTN-0113). Over the past decade, she has authored or co-authored more than 35 CTN publications. Beyond her CTN work, Dr. Lapham leads federally funded research focused on adolescent behavioral health screening, cannabis use and related health outcomes, and patient-centered approaches to the treatment of alcohol and substance use disorders. She is Multiple Principal Investigator of the NIH-funded Options Trial, a pragmatic study testing strategies to support shared decision-making for primary care patients with alcohol use disorder, and Principal Investigator of a NIDA-funded study evaluating longitudinal cannabis use patterns and outcomes across the lifespan. She also mentors emerging investigators in addictions health services research.

Core Investigators

Core investigators are supported by the HSN and bring a breadth of expertise and leadership to concept and protocol development. Our core investigators bring expertise in leading trials, statistical methods, and qualitative methods.

• Andrea Altschuler, PhD
• Jennifer Bobb, PhD
• Jason Glanz, PhD
• Katharine Bradley, MD, MPH
• Komal Narwaney, PhD
• Anh Nguyen, PhD
• Joshua Nugent, PhD
• Stacy Sterling, DrPH, MSW, MPH

Affiliate Investigators

Affiliate investigators include additional senior investigators who can lead CTN trials, mid-career investigators with important expertise to support CTN trials, and early-stage investigators who will be mentored and collaborate in executing Node agendas. Many are embedded within affiliate health systems. 

• Bobbi Jo Yarborough, PsyD
• Claire Simon, MD, MS
• Clarissa Hsu, PhD
• David Smelson, PsyD
• Deborah Rinehart, PhD
• Emily Williams, PhD, MPH
• Helen Jack, MD
• Jenn Coker, PhD, MPH, FASIA
• Jo Ann Shoup, PhD, MSW
• Joseph Glass, PhD, MSW
• Julie Angerhofer, PhD, MPH
• Kelly Young-Wolff, PhD, MPH
• Kristina Phillips, PhD
• Laura Palombi, PharmD, MPH
• Lisa Saldana, PhD
• Lynn DeBar, PhD, MPH
• Madeline Frost, PhD, MPH
• Melissa Harry, PhD, MSW
• Melissa Poulsen, PhD, MPH
• Michael Horberg, MD, MAS
• Michael Bushey, MD, PhD
• Morgan Justice, PhD, MA
• Noorie Hyun, PhD
• Paige Wartko, PhD, MPH
• Stanley Xu, PhD, MS
• Susan Calcaterra, MD, MPH
• Teaniese (Tina) Davis , PhD, MPH
• Theresa (Tessa) Matson, PhD, MPH
• Vanessa Palzes, MPH
• Verena Metz, PhD​